3min read
PREVIOUS ARTICLE ASX opens higher as health sha... NEXT ARTICLE ResMed takes Big Data approach...

Medical products company ResMed says it lifted revenue in the three months ended March 31 by 12 per cent, to $US662.2 million ($A952.2 m).

Resmed said it made $US157 million ($224m) in profit, up 15 per cent from the same period in 2018.

The board of directors declared a quarterly cash dividend of 37 US cents per share.

At 1029 AEST, Resmed shares were up 92 cents, or 6.25 per cent, to $15.74, their highest level since January.

The San Diego-based, ASX-listed company produces products to treat sleep disorders.